Jin Xian, Huang Yan, Yoo Hyo Kyung, Lee Se Yeon, Chun Yang Sook, Hong Ki Yong, Chang Hak
Department of Plastic and Reconstructive Surgery, Seoul National University College of Medicine, Seoul, 03080, Korea.
Department of Interdisciplinary Program in Stem Cell Biology, Seoul National University College of Medicine, Seoul, 03080, Korea.
Aesthetic Plast Surg. 2023 Feb;47(1):412-422. doi: 10.1007/s00266-022-03021-3. Epub 2022 Aug 2.
Cell-assisted lipotransfer (CAL) is a novel technique for fat grafting that combines the grafting of autologous fat and adipose-derived stromal cells (ASCs) to enhance fat graft retention; however, its oncologic safety is controversial.
Herein, we investigated the oncologic safety of CAL for breast reconstruction using a murine model of residual breast cancer. Various concentrations of 4T1 cells (murine breast cancer cells) were injected into female mastectomized BALB/c mice to determine the appropriate concentration for injection. One week after injection, mice were divided into control (100 μL fat), low CAL (2.5 × 10 ASCs/100 μL fat), and high CAL (1.0 × 10 ASCs/100 μL fat) groups, and fat grafting was performed. The injection of 5.0 × 10 4T1 cells was appropriate to produce a murine model of residual breast cancer.
The weight of the fat tumor mass was significantly higher in the high CAL group than in the other groups (p < 0.05). However, the estimated tumor weight was not significantly different between the groups. Additionally, the fat graft survival rate was significantly higher in the high CAL group than in the control and low CAL groups (p < 0.05). No significant difference was noted in the percentage of Ki-67-positive cells, suggesting that tumor proliferation was not significantly different between the groups.
In summary, CAL significantly improved fat graft survival without affecting tumor size and proliferation in a murine model of residual breast cancer. These results highlight the oncologic safety of CAL for breast reconstruction.
This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
细胞辅助脂肪移植（CAL）是一种新型的脂肪移植技术，它将自体脂肪移植与脂肪来源的基质细胞（ASC）相结合，以提高脂肪移植的留存率；然而，其肿瘤学安全性存在争议。
在此，我们使用残余乳腺癌小鼠模型研究了CAL用于乳房重建的肿瘤学安全性。将不同浓度的4T1细胞（小鼠乳腺癌细胞）注射到雌性乳腺切除的BALB/c小鼠体内，以确定合适的注射浓度。注射一周后，将小鼠分为对照组（100μL脂肪）、低CAL组（2.5×10个ASC/100μL脂肪）和高CAL组（1.0×10个ASC/100μL脂肪），并进行脂肪移植。注射5.0×10个4T1细胞适合建立残余乳腺癌小鼠模型。
高CAL组的脂肪肿瘤块重量显著高于其他组（p<0.05）。然而，各组间估计的肿瘤重量无显著差异。此外，高CAL组的脂肪移植存活率显著高于对照组和低CAL组（p<0.05）。Ki-67阳性细胞百分比无显著差异，表明各组间肿瘤增殖无显著差异。
总之，在残余乳腺癌小鼠模型中，CAL显著提高了脂肪移植存活率，且不影响肿瘤大小和增殖。这些结果凸显了CAL用于乳房重建的肿瘤学安全性。
本期刊要求作者为每篇适用循证医学排名的投稿指定证据水平。这排除了综述文章、书评以及涉及基础科学、动物研究、尸体研究和实验研究的手稿。有关这些循证医学评级的完整描述，请参阅目录或作者在线指南www.springer.com/00266 。
